-0.003 (-15.789%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Strong
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Telephone
61.8.9389.3130
Address
Suite 102 Level 1 55 Collins Street Melbourne, Victoria (VIC) 3000
Description
Neurotech International Ltd. engages in the research, design, development, and manufacture of medical devices and solutions in Australia. Its product includes Mente Autism for the diagnosis and treatment of autism. The company was founded on January 15, 2016 and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.07
Trade Value (12mth)
AU$6,729.00
1 week
0%
1 month
35.71%
YTD
-66.07%
1 year
-72.86%
All time high
0.49
EPS 3 yr Growth
112.50%
EBITDA Margin
%
Operating Cashflow
-$9m
Free Cash Flow Return
-121.50%
ROIC
-142.70%
Interest Coverage
N/A
Quick Ratio
11.30
Shares on Issue (Fully Dilluted)
1050m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
05 September 25 |
Release of Shares from Voluntary Escrow
×
Release of Shares from Voluntary Escrow |
|
29 August 25 |
Appendix 4E & Annual Report to shareholders
×
Appendix 4E & Annual Report to shareholders |
|
29 August 25 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
|
31 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
10 July 25 |
Change of Registered Address & Principal Place of Business
×
Change of Registered Address & Principal Place of Business |
|
09 July 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
|
07 July 25 |
New Scientific Publication of Phase I/II Rett Syndrome Trial
×
New Scientific Publication of Phase I/II Rett Syndrome Trial |
|
16 June 25 |
NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor
×
NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor |
|
06 June 25 |
NTI164 to be presented at IRSF Annual Scientific Meeting
×
NTI164 to be presented at IRSF Annual Scientific Meeting |
|
02 June 25 |
Positive Human PK Study Results for NTI164
×
Positive Human PK Study Results for NTI164 |
|
05 May 25 |
NTI164 Preclinical Toxicology Studies Update
×
NTI164 Preclinical Toxicology Studies Update |
|
28 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
16 April 25 |
Updated Trading Policy
×
Updated Trading Policy |
|
02 April 25 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
|
02 April 25 |
Application for quotation of securities - NTI
×
Application for quotation of securities - NTI |
|
02 April 25 |
Secondary Trading Notice
×
Secondary Trading Notice |
|
01 April 25 |
Resignation of Executive Director
×
Resignation of Executive Director |
|
31 March 25 |
European Commission grants NTI164 ODD for Rett Syndrome
×
European Commission grants NTI164 ODD for Rett Syndrome |
|
26 March 25 |
Retraction of Statement
×
Retraction of Statement |
|
24 March 25 |
New Scientific Publication of Phase I/II Autism Trial
×
New Scientific Publication of Phase I/II Autism Trial |
|
20 March 25 |
Neurotech Presentation at NWR Virtual Healthcare Conference
×
Neurotech Presentation at NWR Virtual Healthcare Conference |
|
18 March 25 |
Neurotech to present at NWR Virtual Healthcare Conference
×
Neurotech to present at NWR Virtual Healthcare Conference |
|
27 February 25 |
Positive Opinion on OMPD for NTI164 in Europe
×
Positive Opinion on OMPD for NTI164 in Europe |
|
27 February 25 |
Appendix 4D and Half Year Accounts
×
Appendix 4D and Half Year Accounts |
|
24 February 25 |
Notification regarding unquoted securities - NTI
×
Notification regarding unquoted securities - NTI |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
